GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » Total Liabilities

FibroBiologics (STU:SG0) Total Liabilities : €6.97 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Total Liabilities?

FibroBiologics's Total Liabilities for the quarter that ended in Sep. 2024 was €6.97 Mil.

FibroBiologics's quarterly Total Liabilities declined from Mar. 2024 (€14.04 Mil) to Jun. 2024 (€10.50 Mil) and declined from Jun. 2024 (€10.50 Mil) to Sep. 2024 (€6.97 Mil).

FibroBiologics's annual Total Liabilities increased from Dec. 2021 (€1.56 Mil) to Dec. 2022 (€8.33 Mil) and increased from Dec. 2022 (€8.33 Mil) to Dec. 2023 (€9.69 Mil).


FibroBiologics Total Liabilities Historical Data

The historical data trend for FibroBiologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Total Liabilities Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Total Liabilities
1.56 8.33 9.69

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.59 9.69 14.04 10.50 6.97

FibroBiologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

FibroBiologics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.421+(1.27+1.3322676295502E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=9.69

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=10.84-1.149
=9.69

FibroBiologics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.016+(0.951+-3.3306690738755E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.97

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=9.433-2.466
=6.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroBiologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics Business Description

Comparable Companies
Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

FibroBiologics Headlines

No Headlines